216762
Seminar
SoSe 19: The Drug Discovery Process in the Pharmaceutical Industry - From target to hit identification / Wirkstoffentwicklung - Vom target zur hit-Findung
Roman Hillig, Christoph Rademacher
Hinweise für Studierende
Die Teile (I im SS und II im WS) können in beliebiger Reihenfolge besucht werden, sie sind nicht aufbauend.
Kommentar
Inhalte:
1. Introduction;
2. Protein/Ligand Interactions;
3. Target Discovery and Hit Finding;
4. Nuclear Magnetic Resonance Methods in Drug Discovery;
5. Fragment-based Drug Design;
6. Protein Kinases as a Typical Target Family;
7. Protein Crystallography in Drug Discovery;
8. GPCRs as a Typical Target Family.
Dr. R. Hillig: roman.hillig@bayer.com Dr. C. Rademacher: christoph.rademacher@mpikg.mpg.de Schließen
1. Introduction;
2. Protein/Ligand Interactions;
3. Target Discovery and Hit Finding;
4. Nuclear Magnetic Resonance Methods in Drug Discovery;
5. Fragment-based Drug Design;
6. Protein Kinases as a Typical Target Family;
7. Protein Crystallography in Drug Discovery;
8. GPCRs as a Typical Target Family.
Dr. R. Hillig: roman.hillig@bayer.com Dr. C. Rademacher: christoph.rademacher@mpikg.mpg.de Schließen